Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Exp Neurol. 2010 Jun 28;225(1):210–218. doi: 10.1016/j.expneurol.2010.06.017

Figure 4. Western blot analyses of p-GSK-3β levels in striata [A] and inferior frontal gyri [IFG] [B] from control, PD and PDD groups.

Figure 4

Western blot analyses of p-Tau levels were conducted using antibodies to detect phosphorylation of GSK-3β at Y216. Blots are from representative experiments, while the graph is a summary of quantitation of protein levels normalized against total GSK-3β [nonphosphorylated form] in samples, from striata of 17 PD cases, 18 with PDD and 22 controls and IFG from 9 PD cases, 7 PDD and 9 controls. * denotes p<0.01 for PD and PDD groups compared to controls, while † denotes p<0.01 for PDD compared to PD.